One hundred million treatments of...an antimalarial developed especially for children...have been delivered by Novartis to 39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announced...Coartem® Dispersible is the product of the partnership between MMV and Novartis. It is the first WHO prequalified child-friendly artemisinin-combination therapy (ACT) and addresses an unmet need for paediatric medicines. Young children in Africa are disproportionately affected by malaria, with 86% of malaria deaths occurring in children under the age of five years...“This is indeed a landmark achievement for both Novartis and MMV,” said MMV’s CEO, David Reddy...“Reaching the 100 million milestone in less than 3 years is the culmination of a successful collaboration between Novartis and MMV,” said Linus Igwemezie, Head of the Novartis Malaria Initiative.